Skip to main content
HomeInvestors hub

Photocure Investor Hub

Investment highlights

A commercial-stage company focused on bladder cancer

Hexvix®/Cysview® is a product for the detection of bladder cancer:

  • Established position as an innovation leader in the large and underserved bladder cancer treatment market
  • Treatment guidelines and reimbursement supports market penetration
  • In excess of NOK 500 million in global revenue in 2024
  • Specialist salesforce established in North America and Europe with additional potential value in other territories through our partners; Asieris MediTech Co., Ltd. (China), Endotherapeutics Group (Australia/New Zealand), Genotests (Chile) and IGL Medical (Israel)

Read the corporate overview.

Value-building opportunity

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories
  • Potential for FDA to down-classify blue light cystoscopy and open the 510k pathway to enable more manufacturers to enter the U.S. market
  • Opportunity for Photocure to launch a proprietary flexible blue light cystoscope system to expand the surveillance market globally
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure

Investor news

NEWS POST
Photocure starts up commercial operations in Spain
Oslo, Norway
26 June 2025
NEWS POST
New publication: Higher level of use of BLC improves bladder cancer patient outcomes
Oslo, Norway
25 June 2025
OSE Notice
Photocure ASA - Share option grant
Oslo, Norway
23 June 2025
NEWS POST
Asieris will present Cevira trial data and showcase Hexvix at the IPA congress
Oslo, Norway
6 June 2025
OSE Notice
Photocure ASA: Results for the first quarter of 2025
Oslo, Norway
8 May 2025
OSE Notice
Photocure ASA: Annual general meeting held
Oslo, Norway
5 May 2025
OSE Notice
Photocure ASA: Invitation to presentation of first quarter 2025 financial results
Oslo, Norway
30 April 2025
PRESS-RELEASE
Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
Oslo, Norway
29 April 2025
OSE Notice
Photocure ASA - Notice of the Annual General Meeting 5 May 2025
Oslo, Norway
11 April 2025
OSE Notice
Photocure ASA: Annual Report 2024
Oslo, Norway
11 April 2025
OSE Notice
Photocure ASA: Transactions made under share buyback program
Oslo, Norway
2 April 2025
OSE Notice
Photocure ASA: Transactions made under share buyback program
Oslo, Norway
31 March 2025
OSE Notice
Photocure ASA - Share option grant to Vice President and General Manager EMEA
Oslo, Norway
26 March 2025
PRESS-RELEASE
Photocure appoints Jane Healy as Vice President and General Manager EMEA
Oslo, Norway
26 March 2025
PRESS-RELEASE
Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer
Oslo, Norway
24 March 2025
OSE Notice
Photocure ASA: Initiation of a share buyback
Oslo, Norway
19 March 2025

Latest reports

Event highlights

Conferences

Handelsbanken Nordic Small & Mid Cap Seminar

3 Jun 2025 - 4 Jun 2025

Congresses

Canadian Urological Association 2025 Annual Meeting (CUA)

27 Jun 2025 - 27 Jun 2025https://cuameeting.org/

Congresses

German Urology Association: DGU Congress 2025

17 Oct 2025 - 20 Oct 2025https://www.urologenportal.de/fachbesucher/urologische-kongresse/77-dgu-kongress.html

Analyst coverage Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management. Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

ABG Sundal Collier

Georg Tigalonov-Bjerke, MD
Tel: +47 22 01 60 84

DNB Bank ASA

Geir Hillier Holom
Tel: +47 977 66 583
 

Norne Securities AS

Justė Subatavičiūtė
Tel: (+370) 605 82 527